<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853020</url>
  </required_header>
  <id_info>
    <org_study_id>1211011055</org_study_id>
    <nct_id>NCT01853020</nct_id>
  </id_info>
  <brief_title>Cannabinoids and Cerebellar-Motor Functioning</brief_title>
  <official_title>Cannabinoids and Cerebellar-Motor Functioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the dose-related effects of
      delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor
      functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of the current proposal is to investigate whether acute, IV ∆9-THC
      administration mediates cerebellar versus forebrain-dependent associative learning in humans
      as assessed with eyeblink conditioning (EBC). In addition, a battery of motor function tests
      will also be administered (the CANTAB motor screening test, Grooved Pegboard Motor Task,
      paced finger tapping).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebellum Dependent Associative Learning (% CRs)</measure>
    <time_frame>Measured +15 minutes after infusion</time_frame>
    <description>% conditioned responses (CRs) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebellum Dependent Associative Learning (CR Latency)</measure>
    <time_frame>Measured +15 minutes after infusion</time_frame>
    <description>conditioned response (CR) Latency will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Completion of the Grooved Pegboard Motor Task (Reaction Time/Accuracy)</measure>
    <time_frame>Measured +45 minutes after infusion</time_frame>
    <description>Total time taken to complete the grooved pegboard tasks will be the dependent measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CANTAB Motor Screening Test (Reaction Time)</measure>
    <time_frame>Measured +45 minutes after infusion</time_frame>
    <description>Using a touch screen, reaction time to touch a target will be the dependent measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CANTAB Motor Screening Test (Accuracy)</measure>
    <time_frame>Measured +45 minutes after infusion</time_frame>
    <description>Using a touch screen, accuracy to touch a target will be the dependent measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Paced Finger Tapping (Correct Responses)</measure>
    <time_frame>Measured +45 minutes after infusion</time_frame>
    <description>Using a button on a computer keyboard, correct responses will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Paced Finger Tapping (Reaction Time)</measure>
    <time_frame>Measured +45 minutes after infusion</time_frame>
    <description>Using a button on a computer keyboard, reaction time and tapping variability will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>THC intoxication, as measured by the Visual Analog Scale (Total Score)</measure>
    <time_frame>Baseline; +45, +100, +240 minutes after infusion</time_frame>
    <description>0 being none; 100 being completely</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Cannabis</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or &quot;joint&quot;. Administered intravenously over 10 minutes.
Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or &quot;joint&quot;. Administered intravenously over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC</intervention_name>
    <description>Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or &quot;joint&quot;. Administered intravenously over 10 minutes.
Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or &quot;joint&quot;. Administered intravenously over 10 minutes.</description>
    <arm_group_label>THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have used cannabis at least once in their lifetime

          -  No cannabis use in the past month

          -  Men and women aged 21 to 35 years (extremes included) on the day of the first dosing

        Exclusion Criteria:

          -  Hearing deficits

          -  Psychiatric or mental disorders

          -  Hearing Deficits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 25, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Patrick D. Skosnik</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cannabinoids</keyword>
  <keyword>Eyeblink Conditioning</keyword>
  <keyword>EBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

